Pulse Medical Introduced Novel μFR® system

Pulse Medical introduced novel key algorithm for μFR®. This algorithm represents a fast computation methodology for determining fractional flow reserve (FFR) from multiple imaging data.

The μFR is an angio-based physiological assessment tool that does not require a pressure wire or hyperemic agents. The μFR (microvascular flow reserve) can be used throughout the entire percutaneous coronary intervention (PCI) procedure, encompassing various stages of assessment and optimisation.

The μFR is a novel physiological assessment tool used in angiography procedures. Unlike traditional methods that require a pressure wire or hyperaemic agents, the μFR offers a broader range of indications and is designed to be more affordable.

One of the key advantages of μFR is its ability to be used throughout the entire percutaneous coronary intervention (PCI) procedure. It offers precise physiology assessment at the pre-PCI stage, allowing clinicians to evaluate the functional status of the coronary arteries before performing any interventions.

The μFR® has been supported by several robust clinical studies that demonstrate its positive outcomes. A notable trial called FAVOR III China provides significant evidence. According to this trial's 1-year follow-up, the use of μFR® resulted in a 35 percent reduction in major adverse cardiac events (MACE) risk.

Cardiovascular diseases remain the leading global cause of mortality, resulting in approximately 17.9 million death in 2019. To address this significant health challenge, the use of μFR® as a physiological assessment tool holds the potential to provide valuable insights to physicians and contribute to more effective and precise treatments for patients.